Ivy gourd leaf extract,
does it really help with Improved fasting glucose, postprandial glucose, and HbA1c in type 2 diabetes or prediabetes?
research showsIvy gourd is rated C because several human randomized trials directly evaluated glycemic surrogates in type 2 diabetes and prediabetes. A 60-person trial of 1 g/day extract and a 158-person trial of a 500-mg/day leaf preparation reported improvements in fasting glucose, some postprandial measures, and HbA1c. A 48-person prediabetes trial improved fasting and postprandial glucose but not HbA1c. Most studies were conducted in a single country for about 12 weeks, and preparations and plant parts differed, so prevention of long-term complications and attribution from commercial combinations to ivy gourd alone are not established.
ads claimMarketing expands the evidence into natural insulin, diabetes treatment, or normalization of HbA1c without medication. The evidence concerns short-term laboratory markers in mild, newly diagnosed, or prediabetic populations, not complication prevention or drug replacement. Results from combinations such as Sugar Balance with bougainvillea and Madagascar periwinkle, or from PreCrea, do not belong to ivy gourd alone.
Useful facts when choosing a product
- No ivy-gourd product approved and distributed in Korea as a diabetes medicine was identified. Consumers may encounter direct-import single-ingredient capsules or imported combinations of multiple glucose-oriented ingredients.
- Isolated-ingredient trials used leaf powder 1.8 g/day, alcoholic extract 1 g/day, freeze-dried aqueous leaf preparation 500 mg/day, or hydroalcoholic extract 1 g/day.
- The registered Sugar Balance combination contained ivy gourd 200 mg, bougainvillea 30 mg, and Madagascar periwinkle 20 mg, while PreCrea combined ivy gourd with gymnema, fenugreek, chromium, and biotin.
- Glucose may fall further when combined with diabetes medication, so self-monitoring and clinician review are appropriate. Long-term safety and pregnancy or lactation evidence are inadequate, and prescribed treatment must not be replaced.
What the research actually shows
Azad Khan 1979 gave untreated adults with diabetes leaf powder 1.8 g/day or placebo for six weeks and reported improved two-hour postprandial glucose in 32 participants. Kuriyan 2008 assigned 60 people with newly diagnosed mild type 2 diabetes to an alcoholic extract 1 g/day or placebo for 90 days and reported improved fasting glucose, postprandial glucose, and HbA1c. Wasana 2021 randomized 158 people to a 500-mg/day freeze-dried aqueous leaf preparation or placebo; among 145 completers, fasting glucose, insulin, HbA1c, and HOMA-IR improved. Pickering 2023 administered a 1-g/day hydroalcoholic extract for 12 weeks in 48 people with prediabetes; fasting and two-hour postprandial glucose improved, but HbA1c was null. PreCrea 2016 improved HbA1c but was an industry-funded combination of ivy gourd, gymnema, fenugreek, chromium, and biotin, so it was not counted as isolated-ingredient efficacy.
Why this is classified as C (56)
Several isolated ivy-gourd randomized trials repeatedly improved glycemic surrogates, placing the evidence near the top of C. Studies are short, geographically and formulation heterogeneous, and HbA1c was null in prediabetes. No direct long-term clinical outcome exists, and commercial combinations cannot establish ingredient attribution, so the final rating is C with 56 points. Hypoglycemia risk and product differences are separated into safety and product facts.
Counterpoint. Short-term laboratory improvement alongside diet and exercise remains possible in mild or newly diagnosed diabetes. That does not establish prevention of complications or replacement of standard medication.
Rejudgment record. New verdict — Several small short-term trials of isolated leaf preparations were positive for fasting and postprandial glucose and some HbA1c outcomes, but HbA1c was null in prediabetes and formulation heterogeneity, absence of long-term clinical outcomes, and inability to attribute combination effects limit the grade to C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved fasting and postprandial glucose with an isolated ivy-gourd preparation | C | Positive signals recur in several short randomized trials, but preparations, doses, and populations differ. |
| Improved HbA1c and long-term glycemic control | C | Some diabetes trials improved HbA1c, but the prediabetes trial was null and evidence beyond 12 weeks or on complications is absent. |
| Attribution of combination-product effects to ivy gourd | ? | Trials combining bougainvillea and periwinkle or gymnema, fenugreek, chromium, and biotin did not isolate ivy gourd's contribution. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Azad Khan AK et al. 1979 | Double-blind placebo-controlled clinical trial | 6 | Inadequately reported; academic-institution study | Fasting and two-hour postprandial glucose and glucose tolerance | Reported improved two-hour postprandial glucose with leaf powder 1.8 g/day. | Older small direct signal |
| Kuriyan R et al. 2008 | Randomized double-blind placebo-controlled trial | 90 | Academic-institution study; no commercial funding reported | Fasting glucose, postprandial glucose, and HbA1c | All three markers improved versus placebo with alcoholic extract 1 g/day. | Key isolated-extract randomized trial |
| Wasana KGP et al. 2021 | Randomized double-blind placebo-controlled trial | 3 | Sri Lankan National Research Council development project and academic institutions | Fasting glucose, HbA1c, insulin, HOMA-IR, lipids, and safety | Reported placebo-adjusted improvements of about 22 mg/dL in fasting glucose and 0.77 percentage points in HbA1c with a 500-mg/day leaf preparation. | Largest short-term randomized trial |
| Pickering E et al. 2023 | Single-site randomized double-blind placebo-controlled trial | 12 | Australian academic research with some product-related support reported | Fasting glucose as primary; two-hour postprandial glucose, insulin, and HbA1c as secondary | Fasting and postprandial glucose improved, but HbA1c and most insulin measures were null. | Conflicting evidence extending to prediabetes |
| Thacker H et al. 2016 PreCrea trial | Multicenter randomized double-blind placebo-controlled combination trial | 12 | Funded by PreEmptive Meds and Abbott | HbA1c, fasting glucose, lipids, and safety | The combination improved HbA1c, but gymnema, fenugreek, chromium, and biotin prevented attribution to ivy gourd alone. | Combination evidence without ingredient attribution |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Ivy gourd leaf extract x improved glycemia in type 2 diabetes or prediabetes — Evidence Grade C·56. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/ivy-gourd-type-2-diabetes-prediabetes-glycemia/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.